This test has demonstrated clinical utility in the prediction of prostate cancer biopsy outcomes in men with elevated PSA levels, abnormal DRE results or after a prior negative biopsy, but persistently abnormal PSA levels. Here, KLK3 is linked to prostate carcinoma.